温胃颗粒联合莫沙必利治疗功能性消化不良的临床研究

发布时间：2018-05-26 12:15

本文选题：功能性消化不良 + 脾胃虚寒证　；参考：《天津医科大学》2014年硕士论文

【摘要】：目的：观察温胃颗粒联合莫沙必利治疗脾胃虚寒型功能性消化不良(FD)的临床疗效、安全性及复发率。方法：将符合纳入标准的120例患者随机分为：温胃颗粒组(A组)、莫沙必利组(B组)、温胃颗粒+莫沙必利组(C组),每组均为40例,分别给予温胃颗粒剂、莫沙必利、温胃颗粒+莫沙必利口服,疗程均为4周。观察并记录治疗前后患者主要症状的改善情况,对各症状进行评分。观察并记录不良反应情况,评价药物安全性。治疗结束后随访8周,观察患者有无病情反复。结果：1.总有效率比较：治疗后,三组总有效率分别为65.00%、62.50%、92.50%。三组相比,C组优于A、B组(P0.05),而A、B两组间比较差异无统计学意义(P0.05)。 2.在症状总积分方面,三组治疗后较治疗前均有明显改善(P0.01)。但治疗后三组比较,C组优于A、B两组(P0.05),而A、B两组间比较差异无统计学意义(P0.05)。治疗后C组在改善患者脘腹不适、上腹疼痛、早饱、嗳气方面,疗效优于A、B组(P0.01或P0.05)。 3.治疗过程中,B组有2位患者出现轻微头晕,C组有2位患者出现轻微腹胀,但患者均可耐受,且症状短时间内缓解,用药结束后消失,故未中止治疗观察。三组不良反应发生率比较,差异无统计学意义(P0.05) 4.复发率比较：在8周的随访过程中,A组复发率为42.31%；B组复发率为52.00%；C组复发率为16.21%。三组相比,C组明显低于A、B组,差异有统计学意义(P0.05)。结论：1.温胃颗粒联合莫沙必利治疗脾胃虚寒型FD具有较好的临床效果,对患者各项临床症状均有明显的改善作用。 2.温胃颗粒联合莫沙必利治疗FD无明显毒副作用,安全性较好。 3.温胃颗粒联合莫沙必利治疗FD能减少复发率,值得进一步研究及推广。
[Abstract]:Objective: To observe the clinical efficacy, safety and relapse rate of Wen Wei granule combined with mosapride in the treatment of functional dyspepsia (FD) of spleen stomach deficiency cold.
Methods: 120 patients were randomly divided into two groups: WWEN Wei granule group (group A), mosapride group (group B), wwg + mosapride group (group C), 40 cases in each group, which were given warm stomach granules, mosapride, wwg + mosapride and oral administration for 4 weeks. The changes of main symptoms before and after treatment were observed and recorded. The symptoms were scored. The adverse reactions were observed and recorded. The safety of the drugs was evaluated. After the treatment, the patients were followed up for 8 weeks to observe whether the patients had relapse.
Results: 1. the total effective rate was compared: after treatment, the total effective rate of the three groups was 65%, 62.50% and 92.50%. three compared to group C was superior to A and group B (P0.05), but there was no statistical difference between the A and the B two groups (P0.05).
2. in total symptom score, the three groups were significantly improved after treatment (P0.01). But after treatment, group C was better than A and B two (P0.05), while A, B two groups had no significant difference (P0.05). The curative effect of group C in improving patients with abdominal discomfort, upper abdominal pain, early satiety and belching was better than A, B group (P0.01 or wealth).
3. in group B, 2 patients had slight dizziness, and 2 patients in group C had mild abdominal distention, but the patients could be tolerated, and the symptoms were relieved within a short time, and the treatment was disappearing after the end of drug use. The incidence of adverse reactions in the three groups was not statistically significant (P0.05).
4. comparison of recurrence rate: in the 8 week follow-up process, the recurrence rate of group A was 42.31%, and the recurrence rate in group B was 52%, and the recurrence rate of group C was compared to group 16.21%. three, and group C was significantly lower than that of A, B group, the difference was statistically significant (P0.05).
Conclusion: 1.. Warming stomach particles combined with Mosapride has a good clinical effect in treating spleen and stomach deficiency cold type FD, and has significant improvement on clinical symptoms of patients.
2. Wen Wei granule combined with Mosapride has no obvious side effects in treating FD.
3. warming stomach particles combined with mosapride in the treatment of FD can reduce the recurrence rate, which is worthy of further research and promotion.
【学位授予单位】：天津医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R57

【参考文献】